Xenon Pharmaceuticals (XENE)

• Market cap: $2.81B
• 1 day: -0.44%
• 5 days: 2.22%
• 1 month: 13.86%
• 3 months: -5.61%
• 6 months: -8.81%
• Year to date: -4.90%
• 1 year: -6.03%
• 5 years: 194.75%
• 10 years: 188.30%
• Sector: Healthcare
• Industry: Biotechnology

About: Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Employees: 327

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

5,216% more call options, than puts

Call options by funds: $4.36M | Put options by funds: $82K

45% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 20

44% more funds holding in top 10

Funds holding in top 10: 9 [Q3] → 13 (+4) [Q4]

3% more funds holding

Funds holding: 201 [Q3] → 208 (+7) [Q4]

1.24% more ownership

Funds ownership: 98.82% [Q3] → 100.06% (+1.24%) [Q4]

1% more capital invested

Capital invested by funds: $2.95B [Q3] → $2.99B (+$41.4M) [Q4]

6% less repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 69

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $52 36% upside
• Avg. target: $57 50% upside
• High target: $67 75% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Goldman Sachs Paul Choi 67% 1-year accuracy 10 / 15 met price target	36% upside $52	Buy Maintained	17 Apr 2025
HC Wainwright & Co. Douglas Tsao 26% 1-year accuracy 44 / 171 met price target	39% upside $53	Buy Reiterated	24 Feb 2025
Deutsche Bank David Hoang 12% 1-year accuracy 2 / 17 met price target	75% upside $67	Buy Initiated	11 Feb 2025